CTOs on the Move

Slayback Pharma

www.slayback-pharma.com

 
Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Slayback Pharma raised $50M on 01/06/2020

Similar Companies

Headway

Headway.co is a digital marketing agency that offers holistic services to help businesses scale their growth. From innovative digital strategies to custom web design and development, Headway.co specializes in conversion optimization and delivering meas...

Emendo Biotherapeutics

Emendo biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy.

Everett Laboratories Inc

Everett Laboratories Inc is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Commonwealth Biotechnologies

Commonwealth Biotechnologies is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PvP Biologics

PvP Biologics is developing an oral enzyme for the treatment of celiac disease. Our mission is to develop a highly-effective therapeutic product to reduce the burden of living with this disease. Towards this end, we are advancing a product candidate designed to break down the immuno-reactive parts of gluten in the stomach and thereby avoid the painful symptoms and damage done in the small intestine from accidental gluten ingestion. Affecting an estimated 2.4 million Americans, celiac disease is significantly more common than inflammatory bowel disease and is associated with acute gastrointestinal symptoms, malnutrition, and increased mortality. The disease is currently treated by a gluten-free diet, which is costly and challenging to maintain strict compliance. Many patients continue to report persistent symptoms despite adhering to a gluten-free diet. The technology was invented at the Institute for Protein Design at University of Washington and exclusively in-licensed by PvP Biologics. We have corporate offices in San Diego and research laboratories in Seattle.